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Abstracts / Urological Science 27 (2016) S53eS83 S65tumor was manipulated. The bladder tumor was resected under close
monitor and careful control of blood pressure. The ﬁnal pathology report
was bladder paraganglioma, a rare bladder tumor.
Conclusion: Paragangliomas are rare neuroendocrine tumors that arise
from the extra-adrenal autonomic paraganglia, small organs consisting
mainly of neuroendocrine cells that are derived from the embryonic neural
crest and have the ability to secrete catecholamines. Sympathetic para-
gangliomas usually secrete catecholamines and are located in the sym-
pathetic paravertebral ganglia of thorax, abdomen, and pelvis. In contrast,
most parasympathetic paragangliomas are nonfunctional and located
along the glossopharyngeal and vagal nerves in the neck and at the base of
the skull. Catecholamine-secreting paragangliomas often present clinically
like pheochromocytomas with hypertension, episodic headache, sweating,
and tachycardia. In the genitourinary tract, the urinary bladder is the most
common site for paragangliomas. Bladder paraganglioma consisted only
0.05% of all bladder tumors. According to literature, bladder para-
ganglioma had similar characteristic as pheochromocytoma, but high
recurrence rated than pheochromocytoma, even with benign or small
tumors. Thus, if bladder paraganglioma was highly suspected, especially
with a large tumor size, partial or radical cystectomy with life-long follow-
up is strongly recommended.
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NDP048:
MIRABEGRON (25MG) IN PATIENTS WITH OVERACTIVE BLADDER IS
EFFECTIVE AND SAFE IN REAL LIFE PRACTICE
Yuan Chi Shen, Yao Chi Chuang. Division of Urology, Kaohsiung Chang Gung
Memorial Hospital and Chang Gung University College of Medicine, Taiwan
Purpose: Antimuscarinic (AM) agents are the mainstay of oral pharma-
cotherapy for overactive bladder (OAB), however, AM-associated adverse
events or insufﬁcient efﬁcacy limited its clinical persistence. Mirabegron is
a potent and selective b3-adrenoceptor agonist that could exert an
inhibitory effect on bladder afferent and OAB symptoms. We conducted a
postmarketing study to evaluate the efﬁcacy and safety of Mirabegron
(25mg) in patients with OAB.
Materials and Methods: The studywas a retrospective consecutive cohort
of 73OAB patients (50male and 23 female) treatedwithMirabegron 25mg.
The outcomes were initially assessed and re-evaluated 4 weeks later using
the uroﬂow study, post-void residual urine and questionnaire with Inter-
national Prostate Symptom Score (IPSS), Overactive Bladder Symptom
Score (OABSS), Urgency Severity Score (USS) and Quality of Life (QOL)
Results: At 4 weeks post-treatment, Mirabegron usage was associated
with a statistically signiﬁcant decrease in OABSS, USS, IPSS-V and IPSS-S
(Shown in Table.1). Furthermore, the nocturia scoring in IPSS questionnaire
was also decrease from 2.8± 1.7 to 2.2± 1.3 (p¼ 0.006). Table.2 showed no
compromise of uroﬂow rate and no increase of post-void residual urine.
Three out of 21 patients (14%) with hypertension was found with elevated
blood pressure, and discontinue Mirabegron treatment after one month of
initial treatment.
Conclusion: This post-marketing surveillance study conﬁrms that Mir-
abegron (25mg) improves clinical outcomes in patients with OAB and the
adverse effects was low.
NDP049:
THE RESULTS OF TRANSURETHRAL VAPORESECTION OF PROSTATE
USING THE REVOLIX LASER: CHI MEI HOSPITAL, LIOUYING
Eric W. Fan. Division of Urology, Department of Surgery, Chi Mei Medical
Center, Liouying, Taiwan
Purpose: Benign prostate hyperplasia (BPH) is a common disorder of men
over the age of ﬁfty. A number of laser based procedures have been
developed to treat the disorder. The potassium titanyl phosphate (KTP)
laser has to been used for vaporization of the prostate. The RevoLix 2
micron continuous wave Laser has been speciﬁcally designed to vaporize
and incise the prostate with good hemostasis.
Materials andMethods: This paper reviews the results of 217 patients that
were treated over a 12 month period with the new RevoLix Laser. The ageranged from 52 to 84 with a mean 67.2 years. The size of the prostate
ranged from 32.0 to 187.6 with a mean 68.2 grams. Prior to laser treatment
patients were examined, 47 patients had acute urine retention, 67 patients
had diabetes mellititus and 89 patients were on anticoagulants. Follow-up
was from 12 to 116 months. The RevoLix Laser was used at a power level
from 60 to 90 watts. An endﬁring 550 micron ﬁber was used with a
continuous ﬂow 26F cystoscope. VapoResection is a protocol whereby the
laser is used to resect and vaporize pieces of prostate similar the traditional
transurethral resection of prostate. Some pieces were ﬂushed out of the
bladder with the morcelation.
Results: All patients experienced 1 to 9 days of mild dysuria and mild
hematuria. 11 of 217 (5.1%) patients required catheterization in the ﬁrst
after treatment. The one year after transurethral VapoResection of Prostate
(TUVRP) the mean international prostatic symptom score (IPSS) decreased
from 23.2. to 11.8, the mean peak uroﬂow rate (UFR) increased from 7.5 to
16.2 mL/sec. Only one of 217 (0.4%) patients needed to check bleeding after
operation. 13 of 217 (6.0%) patients had urethral stricture or bladder neck
contracture 3e32 months later after TUVRP.
Conclusion: However, the results encourage to transurethral vapor-
esection of prostate using the RevoLix Laser for the treatment of BPH.
NDP050:
UROLOGICAL CONDITIONS WERE NOT RARE IN PATIENTS WITH
AMYOTROPHIC LATERAL SCLEROSIS
Tzu-Yu Chuang 1, Wei-Ming Cheng 1,2, Chang-Chi Chang 1,2, Yi-Chun
Chiu 1,2. 1Division of Urology, Department of Surgery, Zhongxiao Branch,
Taipei City Hospital, Taiwan; 2Department of Urology, School of Medicine,
National Yang-Ming University, Taipei, Taiwan
Purpose: Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disorders involving both upper and lower motor neurons. Pa-
tients with ALS would inevitably lose all somatic nerve function, but
autonomic nerve function is relatively preserved. Clinically we observed
that these patients might have variable lower urinary tract symptoms,
which hasn’t been reported in the medical literature. Therefore, we con-
ducted a retrospective observational study to investigate the prevalence of
urinary symptoms in one of the largest ALS referral centers in Taiwan.
Materials andMethods: We retrospectively reviewed patients with ALS in
our institute from January 1st 2014 to March 15th 2016. Those with urinary
symptoms that needed referral to a urologist were included. Age, sex,
comorbidities, initial presentation and duration of ALS, muscle power of
lower extremities, and urinalysis at the time of referral were obtained from
chart review or telephone interview. These data were analyzed with
descriptive statistics. Fisher’s exact test was used to compare possible
associated factors between ALS patients with urinary retention and those
without. P value less than 0.05 was viewed as statistical signiﬁcance.
Results: Sixteen patients have been included, accounting for 12.4% of all
ALS patients in our institute during the study period. Twelve were males
(75%) and four were females (25%). Median age at referral was 61 (39e 79)
years of age. Median duration of ALS was 5 (0.5 e 29) years. Three (18.8%)
patients had type 2 diabetes, and 15 (93.8%) patients needed respiratory
support. Five (41.7%) patients presented initially with dysarthria, while
seven (58.3%) patients were diagnosed with ALS due to weakness of ex-
tremities. Ten (62.5%) patients preserved some degree of muscle power at
the time of urological referral. Refractory lower urinary tract symptoms
were the chief complaints, including voiding symptom predominance in
six (37.5%), storage symptom predominance in four (25.0%), and dysuria in
six patients (37.5%). Pyuria was only presented in two patients with
dysuria. Nine patients were diagnosed with urinary retention after eval-
uation by urologists. Median postvoid residual urine amount was 820
(550e2100) ml. Factors including age, sex, disease duration, residual
muscle power, or initial presentations were failed to show associationwith
the development of urinary retention in patients with ALS.
Conclusion: Urinary symptoms, including voiding and storage symptoms,
as well as dysuriawere not rare in patients with ALS. Urinary retentionwas
the most common urological conditions, but associated factors were failed
to be identiﬁed in the present study. A prospective study recruiting more
patients with ALS would be helpful to predict the development of urinary
retention in this patient population.
